1 (Amended). An immunogenic complex comprising a charged organic complex and a charged antigen, which organic complex and antigen are electrostatically associated.

2 (Amended). The immunogenic complex according to claim 1 wherein said charged organic complex is negatively charged and said antigen is positively charged.

4 (Amended). The immunogenic complex according to claim 2 wherein said charged organic complex is an adjuvant or perivative or equivalent thereof.

5 (Amended). The immunogenic complex according to claim 2 wherein said antigen is a protein or derivative or equivalent thereof and said charged organic complex is an adjuvant or derivative or equivalent thereof.

6 (Amended). The immunogenic complex according to claim 5 wherein said adjuvant is a naturally negatively charged adjuvant which has been modified to increase the degree of its negative charge.

7 (Amended). The imminogenic complex according to claim 5 wherein said protein is a naturally positively charged protein which has been modified to increase the degree of its positive charge.

8 (Twice Amended). The immunogenic complex according to claim 5 wherein said adjuvant is a naturally negatively charged adjuvant which has been modified to increase the degree of its negative charge and said protein is a naturally positively charged protein which has been modified to increase the degree of its positive charge.

16 (Amended). The immunogenic complex according to claim 15 wherein the lipid A is selected from the group consisting of diphosphoryl lipid A and monophosphoryl lipid A.

18 (Amended). A vaccine composition comprising as the active component a charged organic complex and a charged antigen, which charged organic complex and

Serial No. 09/506,011 Attorney Docket No. 017227/0155

antigen are electrostatically associated, together with one or more pharmaceutically acceptable carriers and/or diluents.

19 (Amended). The vaccine composition according to claim 18 wherein said charged organic complex is negatively charged and said antigen is positively charged.

- 21 (Amended). The vaccine composition according to claim 19 wherein said charged organic complex is an adjuvant or derivative or equivalent thereof.
- 22 (Amended). The vaccine composition according to claim 19 wherein said antigen is a protein or derivative or equivalent thereof and said charged organic complex is an adjuvant or derivative or equivalent thereof.
- 23 (Amended). The vaccine composition according to claim 22 wherein said adjuvant is a naturally negatively charged adjuvant which has been modified to increase the degree of its negative charge.
- 24 (Amended). The vaccine composition according to claim 22 wherein said protein is a naturally positively charged protein which has been modified to increase the degree of its positive charge.
- 25 (Amended). The vaccine composition according to claim 22 wherein said adjuvant is a naturally negatively charged adjuvant which has been modified to increase the degree of its negative charge and said protein is a naturally positively charged protein which has been modified to increase the degree of its positive charge.
- 33 (Twice Amended). The vaccine composition according to claim 32 wherein the lipid A is selected from the group consisting of diphosphoryl lipid A and monophosphoryl lipid A.